DEF: 10x Genomics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

10x Genomics will hold its 2025 Annual Meeting of Stockholders virtually on June 3, 2025, to vote on director elections, auditor ratification, and executive compensation.

Summary

• 10x Genomics, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 3, 2025, at 1:30 p.m. PDT.
• Stockholders will vote on three proposals: the election of Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and an advisory vote on executive compensation.
• The board of directors recommends voting FOR the election of the director nominees and FOR the ratification of the auditor and the advisory vote on executive compensation.
• The record date for determining stockholders eligible to vote at the meeting is April 8, 2025.
• The proxy materials, including the proxy statement and annual report on Form 10-K for the year ended December 31, 2024, are available online.
• The company has adopted a notice-only option for delivering proxy materials, meaning stockholders will not automatically receive paper copies unless requested.
• The board of directors has determined that six of the eight directors are independent under Nasdaq rules.
• The company has a clawback policy in place for executive compensation.
• The company prohibits hedging, pledging, and short sales of 10x stock by its personnel.
• The company's compensation committee uses competitive compensation data from a peer group of companies to inform executive pay decisions.
• The company's executive compensation program consists of base salary, an annual incentive plan (AIP), and equity awards (RSUs and PSUs).
• The company's CEO's annual compensation in 2024 was $356,700 lower compared to 2023.
• The company's CEO's target total compensation is below the 50th percentile of the peer group, with base salary and target total cash compensation near the 25th percentile.
• The company's Stock Ownership Policy requires minimum ownership of five times the annual salary of the Chief Executive Officer, two times the annual salary for all other executive officers of the company and three times the amount of the annual base cash retainer paid to non-employee independent directors.
• The company's CEO pay ratio is 39 to 1.

Sentiment

Score: 6

Explanation: The document is primarily factual and procedural, outlining the details of the upcoming annual meeting and related proposals. While there are some positive aspects highlighted, such as the company's governance practices and compensation strategies, the overall tone is neutral and informative.

Positives

• The company has a clawback policy in place, allowing for the recovery of erroneously awarded compensation.
• The company prohibits hedging, pledging, and short sales of 10x stock, aligning executive interests with long-term stockholder value.
• The company's compensation committee uses a peer group to benchmark executive compensation, ensuring competitiveness.
• The company's Stock Ownership Policy requires minimum ownership of five times the annual salary of the Chief Executive Officer, two times the annual salary for all other executive officers of the company and three times the amount of the annual base cash retainer paid to non-employee independent directors.

Negatives

• The company's CEO's target total compensation is below the 50th percentile of the peer group, with base salary and target total cash compensation near the 25th percentile.

Risks

• The cautionary statement regarding forward-looking statements highlights the inherent risks and uncertainties that could cause actual results to differ materially from expectations.

Future Outlook

The company expects the positions of chairman of the board and Chief Executive Officer and President to continue to be held by separate individuals in the future.

Management Comments

• Serge Saxonov, Chief Executive Officer and Director: 'On behalf of the board of directors and the officers and employees of 10x Genomics, Inc., I would like to take this opportunity to thank our stockholders for their continued support.'

Industry Context

The document provides insight into 10x Genomics' corporate governance practices, executive compensation strategies, and financial performance, which are all relevant to understanding the company's position within the competitive life sciences and biotechnology industry.

Comparison to Industry Standards

• The document benchmarks executive compensation against a peer group of companies with annual revenues ranging from 0.5 to 3.0 times our trailing 12-month revenues and market capitalizations between 0.3 and 3.0 times our own.
• The peer group includes ACADIA Pharmaceuticals Inc., Insulet Corporation, Penumbra, Inc., Alteryx, Inc., iRhythm Technologies, Inc., Repligen Corporation, Azenta, Inc., Maravai Lifesciences Holdings, Inc., Shockwave Medical, Inc., Bio-Techne Corp., Natera, Inc., Sotera Health Company, Exact Sciences Corporation, NeoGeonomics, Inc., Veracyte, Inc., Guardant Health, Inc., Nevro Corp., Guidewire Software, Inc., NovoCure Limited.

Management Changes

Corporate Governance

Stakeholder Impact

• Stockholders are encouraged to participate in the annual meeting and vote on the proposals.
• The executive compensation program is designed to attract, retain, and motivate talented individuals to increase stockholder value.
• The company's governance practices aim to ensure transparency and accountability to stakeholders.

Next Steps

• Stockholders are urged to vote promptly and submit their proxy via regular mail, online, or by telephone.
• The board of directors will take into account the outcome of the advisory vote on executive compensation when considering future compensation decisions for named executive officers.

Key Dates

Keywords

proxy statement, annual meeting, executive compensation, directors, auditor, stockholders, governance, 10x Genomics